USCOM LIMITED — Regulatory Filings 2012

May 10, 2012

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

New UK NHS Guidelines include USCOM for improving surgical care.

Friday 11th of May 2012: Uscom (ASX code: UCM).

Uscom Ltd today announced that USCOM has been included in new Intraoperative Fluid Management Technologies Pack by the United Kingdom NHS Technology Adoption Centre. The management pack describes the “What, Why and How” to improve patient management and care during major and high risk surgery by improved management of fluid. The Guidelines have been published “to help Trusts implement the technology and realise the benefits it can bring.”

These NHS guidelines summarise the benefits of implementation of intra-operative fluid management which include proven life savings and improved patient recovery time and cost savings. Thus the adoption of these recommendations will be driven by benefits to patients and health care providers.

USCOM is a new and specialized device for fluid optimization and has the advantage of being extremely accurate and totally noninvasive and is validated for use in neonates, children and adults. Fluid is the most common critical care intervention in neonates, children and adults being performed on many millions of patients per year. While the current recommendations are directed at intraoperative optimization in adults only, recent evidence suggests improvements in fluid management should also be implemented in neonates, children and adults in all clinical applications.

Executive Chairman of Uscom, Rob Phillips said, “Uscom have conceived and built the practice leading USCOM haemodynamic monitor to meet this critical clinical need. This recognition by the NHS is a response to the overwhelming evidence that improved haemodynamic management saves lives and reduces cost. This evidence will inevitably become a driver of adoption in the new cost sensitive health management age all over the world. Doppler has the highest levels of effectiveness for monitoring haemodynamics. While alternate methods are invasive or require sedation, USCOM is totally noninvasive and accurate and so can be used outside the operating room, and has no consumable costs like its competitors. These Government led guidelines are verification of the message Uscom has been spreading for the last 10yrs; improved management of fluid saves lives and money and USCOM is the most accurate and cost effective method. Fluid management is another area in which USCOM is now being recognized as a standard of care.”

References:

http://www.ntac.nhs.uk/

Thiel SW, Kollef MH, Isakow W. Non-invasive stroke volume measurement and passive leg raising predict volume responsiveness in medical ICU patients: an observational cohort study. Critical Care 2009;39:666-688.

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

About Uscom

Uscom Limited is an Australian medical device company which listed on the Australian Stock Exchange in December 2003. Uscom has developed a Non Invasive Cardiac Output Monitor. The USCOM is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency and Intensive Care Medicine and Anesthesia, and is a tool of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

USCOM has global regulatory approval and the device is currently marketed in North America, South America, Europe, the Middle East, Australia & New Zealand, China and SE Asia.

Uscom Contacts Rob Phillips Executive Chairman rob@uscom.com.au

Tom Rowe Company Secretary secretary@uscom.com.au